冠状病毒
蛋白酶
木瓜蛋白酶
病毒学
2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
药品
医学
大流行
授权
2019-20冠状病毒爆发
抗病毒药物
药理学
生物
酶
内科学
传染病(医学专业)
生物化学
疾病
计算机安全
爆发
计算机科学
作者
Cheng San Brian Chia,Siew Pheng Lim
标识
DOI:10.1002/cmdc.202300216
摘要
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is an unprecedented global health emergency causing more than 6.6 million fatalities by 31 December 2022. So far, only three antiviral drugs have been granted emergency use authorisation or approved by the FDA. The SARS-CoV-2 papain-like protease (PLpro ) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis although no inhibitors have yet been approved. This patent review discusses coronavirus PLpro inhibitors reported in patents published between 1 January 2003 to 2 March 2023, giving an overview on the inhibitors that have generated commercial interest, especially amongst drug companies.
科研通智能强力驱动
Strongly Powered by AbleSci AI